## Comparison of SARS-CoV-2 N gene real-time RT-PCR targets and commercially available

## mastermixes

Julianne R Brown<sup>a</sup>, Denise M. O'Sullivan<sup>b</sup>, Divya Shah<sup>a</sup>, Laura Atkinson<sup>a</sup>, Rui PA Pereira<sup>b</sup>, Alexandra S Whale<sup>b</sup>, Eloise J Busby<sup>b</sup>, Jim F Huggett<sup>b,c</sup>, Kathryn Harris<sup>a</sup>

Supplementary Data: Figures S1–S6

Figure S1. Amplification curves using Takara PrimeScript III mastermix for a) Assay A, b) Assay B and c) Assay C



Figure S2. Amplification curves using ThermoFisher Fast Virus mastermix for a) Assay A, b) Assay B and c) Assay C



Figure S3. Amplification curves using ThermoFisher TaqPath mastermix for a) Assay A, b) Assay B and c) Assay C



Figure S4. Amplification curves using Qiagen Quantifast mastermix for a) Assay A, b) Assay B and c) Assay C







Figure S5. Plot of Cq values for N gene transcript dilution series, observed with each Assay (A–C) and mastermix combination in this study

**Figure S6**. Amplification plot from 72 swabs tested using **a**) Qiagen Quantifast Multiplex RT-PCR +R mastermix; **b**) Takara One Step PrimeScript<sup>™</sup> III RT-PCR Kit mastermix, with real-time RT-PCR Assay A on QuantStudio5 thermocycler (red, SARS-CoV-2; blue PDV); **c**) Correlation between Cq values observed with Qiagen and Takara mastermixes





